Citations (34)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (4)
Carol Mansfield, Sandy Srinivas, Connie Chen, A. Brett Hauber, Subramanian Hariharan, Ewa Matczak & Rickard Sandin. (2016) The effect of information on preferences for treatments of metastatic renal cell carcinoma. Current Medical Research and Opinion 32:11, pages 1827-1838.
Read now
Read now
Jamal Zekri, Lydia M Dreosti, Marwan Ghosn, Emad Hamada, Mohamed Jaloudi, Ola Khorshid & Blaha Larbaoui. (2015) Multidisciplinary management of clear-cell renal cell carcinoma in Africa and the Middle East: current practice and recommendations for improvement. Journal of Multidisciplinary Healthcare 8, pages 335-344.
Read now
Read now
Anna M Czarnecka, Cezary Szczylik & Brian Rini. (2014) The use of sunitinib in renal cell carcinoma: where are we now?. Expert Review of Anticancer Therapy 14:9, pages 983-999.
Read now
Read now
Vincenzo Marotta, Maria Domenica Franzese, Michela Del Prete, Maria Grazia Chiofalo, Valeria Ramundo, Raffaella Esposito, Francesca Marciello, Luciano Pezzullo, Annachiara Carratù, Mario Vitale, Annamaria Colao & Antongiulio Faggiano. (2013) Targeted therapy with kinase inhibitors in aggressive endocrine tumors. Expert Opinion on Pharmacotherapy 14:9, pages 1187-1203.
Read now
Read now
Articles from other publishers (30)
Shohei Fukada, Kouji Ohta, Miyuki Sakuma, Misaki Akagi, Hiroki Kato, Takako Naruse, Takayuki Nakagawa, Hideo Shigeishi, Hiromi Nishi, Masaaki Takechi & Tomonao Aikawa. (2023)
Sunitinib promotes apoptosis via p38
MAPK
activation and
STAT3
downregulation in oral keratinocytes
. Oral Diseases.
Crossref
Crossref
Martin BoegemannKatrin SchlackMichael Rink, Stephan Bernhardt, Michael Moran, Marcus Hubbe, Lothar Bergmann, Marianne Schmid & Arne Strauss. (2020) Effect of comorbidities/comedications on sunitinib outcomes for metastatic renal cell carcinoma: the STAR-TOR registry. Future Oncology 16:35, pages 2939-2948.
Crossref
Crossref
I. A. Stepanov, M. A. Shameeva, D. B. Kruchinin, V. A. Byvaltsev & I. A. Shagdurova. (2020) HEMATOTOXIC ADVERSE DRUG REACTIONS ASSOCIATED WITH VASCULAR ENDOTHELIAL GROWTH FACTOR INHIBITORS AND CYTOTOXIC DRUGS IN THE TREATMENT OF GLIOBLASTOMA: A SYSTEMATIC REVIEW. Siberian journal of oncology 19:5, pages 121-130.
Crossref
Crossref
Anikó Maráz, Adrienn Cserháti, Gabriella Uhercsák, Éva Szilágyi, Zoltán Varga, János Révész, Renáta Kószó, Linda Varga & Zsuzsanna Kahán. (2018) Dose escalation can maximize therapeutic potential of sunitinib in patients with metastatic renal cell carcinoma. BMC Cancer 18:1.
Crossref
Crossref
Michelle L. McDonald, Brian R. Lane, Juan Jimenez, Hak J. Lee, Kendrick Yim, Ahmet Bindayi, Zachary A. Hamilton, Charles A. Field, Aaron S. Bloch, Sumi Dey, Sabrina Noyes, Rana McKay, Frederick Millard, Brian I. Rini, Steven C. Campbell & Ithaar H. Derweesh. (2018) Renal Functional Outcome of Partial Nephrectomy for Complex R.E.N.A.L. Score Tumors With or Without Neoadjuvant Sunitinib: A Multicenter Analysis. Clinical Genitourinary Cancer 16:2, pages e289-e295.
Crossref
Crossref
Manuela Schmidinger & Romano Danesi. (2018) Management of Adverse Events Associated with Cabozantinib Therapy in Renal Cell Carcinoma. The Oncologist 23:3, pages 306-315.
Crossref
Crossref
Damian Matak, Klaudia K. Brodaczewska, Monika Lipiec, Łukasz Szymanski, Cezary Szczylik & Anna M. Czarnecka. (2017) Colony, hanging drop, and methylcellulose three dimensional hypoxic growth optimization of renal cell carcinoma cell lines. Cytotechnology 69:4, pages 565-578.
Crossref
Crossref
V. Lieb, M. Rink, D. Sikic & B. Keck. (2016) Nebenwirkungsmanagement von Tyrosinkinaseinhibitoren in der UrologieSide effect management of tyrosine kinase inhibitors in urology. Der Urologe 55:6, pages 805-812.
Crossref
Crossref
D. Sikic, G. Lüdecke, V. Lieb & B. Keck. (2016) Nebenwirkungsmanagement von Tyrosinkinaseinhibitoren in der UrologieSide effect management of tyrosine kinase inhibitors in urology. Der Urologe 55:5, pages 648-652.
Crossref
Crossref
Anna M Czarnecka, Maciej Kawecki, Fei Lian, Jan Korniluk & Cezary Szczylik. (2015) Feasibility, efficacy and safety of tyrosine kinase inhibitor treatment in hemodialyzed patients with renal cell cancer: 10 years of experience. Future Oncology 11:16, pages 2267-2282.
Crossref
Crossref
Mehdi Afrit, Yosra Yahyaoui, Aderrazek Bouzouita, Saoussen Hantous, Soumaya Labidi, Mohamed Chebil, Khaoula Ben Miled, Bernard Escudier & Hamouda Boussen. (2015) Traitements médicaux des cancers du rein localement avancés et/ou métastatiques. La Presse Médicale 44:2, pages 135-143.
Crossref
Crossref
Ay?e Demirci, ?znur Bal, Ay?e Durnali, Ahmet ? Ekinci, Onur E?bah, Necati Alki?Berna ?ks?zo?lu. (2013) Sunitinib-induced severe hypoglycemia in a diabetic patient. Journal of Oncology Pharmacy Practice 20:6, pages 469-472.
Crossref
Crossref
Juan W. Valle, Sandrine Faivre, Richard A. Hubner, Enrique Grande & Eric Raymond. (2014) Practical management of sunitinib toxicities in the treatment of pancreatic neuroendocrine tumors. Cancer Treatment Reviews 40:10, pages 1230-1238.
Crossref
Crossref
David Cella, Mellar P. Davis, Sylvie Négrier, Robert A. Figlin, M. Dror Michaelson, Andrew G. Bushmakin, Joseph C. Cappelleri, Rickard Sandin, Beata Korytowsky, Claudie Charbonneau, Ewa Matczak & Robert J. Motzer. (2014) Characterizing fatigue associated with sunitinib and its impact on health‐related quality of life in patients with metastatic renal cell carcinoma. Cancer 120:12, pages 1871-1880.
Crossref
Crossref
Hiroyuki Takahashi, Hidenori Ojima, Hiroko Shimizu, Junji Furuse, Hiroyuki Furukawa & Tatsuhiro Shibata. (2014) Axitinib (AG-013736), an Oral Specific VEGFR TKI, Shows Potential Therapeutic Utility Against Cholangiocarcinoma. Japanese Journal of Clinical Oncology 44:6, pages 570-578.
Crossref
Crossref
L. Carter, R. A. Hubner & J. W. Valle. 2014. Management of Neuroendocrine Tumors of the Pancreas and Digestive Tract. Management of Neuroendocrine Tumors of the Pancreas and Digestive Tract
141
154
.
Manuela Schmidinger. (2013) Understanding and managing toxicities of vascular endothelial growth factor (VEGF) inhibitors. European Journal of Cancer Supplements 11:2, pages 172-191.
Crossref
Crossref
Daniel Castellano, Alain Ravaud, Manuela Schmidinger, Guillermo De Velasco & Federico Vazquez. (2013) Therapy management with sunitinib in patients with metastatic renal cell carcinoma: Key concepts and the impact of clinical biomarkers. Cancer Treatment Reviews 39:3, pages 230-240.
Crossref
Crossref
Jian-ri Li, Chi-rei Yang, Chen-li Cheng, Hao-chung Ho, Kun-yuan Chiu, Chung-Kuang Su, Wen-Ming Chen, Shian-Shiang Wang, Chuan-Shu Chen, Cheng-Kuang Yang & Yen-chuan Ou. (2012) Efficacy of a protocol including heparin ointment for treatment of multikinase inhibitor-induced hand–foot skin reactions. Supportive Care in Cancer 21:3, pages 907-911.
Crossref
Crossref
Alain Ravaud & Marine Gross-Goupil. (2012) Overcoming resistance to tyrosine kinase inhibitors in renal cell carcinoma. Cancer Treatment Reviews 38:8, pages 996-1003.
Crossref
Crossref
Axel Bex, Martin Gore, Peter Mulders & Cora N. Sternberg. (2012) Recent advances in the treatment of advanced renal cell carcinoma: towards multidisciplinary personalized care. BJU International 110:9, pages 1289-1300.
Crossref
Crossref
Manuela Schmidinger, James Larkin & Alain Ravaud. (2012) Experience with sunitinib in the treatment of metastatic renal cell carcinoma. Therapeutic Advances in Urology 4:5, pages 253-265.
Crossref
Crossref
Jacopo GiulianiFabrizio Drudi. (2012) Immunotherapy and Targeted Therapies in Metastatic Renal Cell Carcinoma: Is There a Preferred Sequence?. Cancer Biotherapy and Radiopharmaceuticals 27:8, pages 513-518.
Crossref
Crossref
Manuela Schmidinger & Jutta Bergler-Klein. (2012) Therapy management of cardiovascular adverse events in the context of targeted therapy for metastatic renal cell carcinoma. International Journal of Urology 19:9, pages 796-804.
Crossref
Crossref
Manuela Schmidinger, Martin Gore, Camillo Porta, Sylvie Négrier & Bernard Escudier. (2012) mRCC management: past, present and future. European Journal of Cancer Supplements 10:2, pages 1-11.
Crossref
Crossref
Laurence AlbigesStéphane OudardSylvie NegrierArmelle CatyGwenaëlle GravisFlorence JolyBrigitte DuclosLionel GeoffroisFrédéric RollandAline GuillotBrigitte LaguerreEric LegouffeFrédéric KohserPierre-Yves DietrichChristine A. TheodoreBernard Escudier. (2012) Complete Remission With Tyrosine Kinase Inhibitors in Renal Cell Carcinoma. Journal of Clinical Oncology 30:5, pages 482-487.
Crossref
Crossref
Sylvie Négrier. (2012) Duration of Targeted Therapy for Metastatic Renal Cell Carcinoma: A Review of Current Practices. Oncology 82:4, pages 189-196.
Crossref
Crossref
. (2011) Current World Literature. Current Opinion in Supportive & Palliative Care 5:3, pages 297-305.
Crossref
Crossref
Nicholas G. Cost, Scott E. DelacroixJr.Jr., Joshua P. Sleeper, Paul J. Smith, Ramy F. Youssef, Brian F. Chapin, Jose A. Karam, Stephen Culp, E. Jason Abel, James Brugarolas, Ganesh V. Raj, Arthur I. Sagalowsky, Christopher G. Wood & Vitaly Margulis. (2011) The Impact of Targeted Molecular Therapies on the Level of Renal Cell Carcinoma Vena Caval Tumor Thrombus. European Urology 59:6, pages 912-918.
Crossref
Crossref
Maria E. Cabanillas, Mimi I. Hu, Jean-Bernard Durand & Naifa L. Busaidy. (2011) Challenges Associated with Tyrosine Kinase Inhibitor Therapy for Metastatic Thyroid Cancer. Journal of Thyroid Research 2011, pages 1-9.
Crossref
Crossref